Genital Diseases, Female News

Genital Diseases, Female	Welcome, Profile Billing Logout

«1 2...70 71 72 73 747576 77 78 79 80...110 111 »

|||||||||| Clinical: Endometrial Scratching for Cryopreserved Embryo Transfer (clinicaltrials.gov) - Mar 19, 2014
P=N/A, N=200, Recruiting, Sponsor: University of Sao Paulo

||||||||||  Orgovyx (relugolix) / Intas, Gedeon Richter, Takeda, ASKA Pharma, Sumitomo Pharma, Pfizer
New P1 trial:  A Phase 1 Study to Evaluate the Effects of Fluconazole and Atorvastatin on the Pharmacokinetics of TAK-385 in Healthy Subjects (clinicaltrials.gov) -  Mar 19, 2014
P1, N=40, Completed,  Sponsor: Millennium Pharmaceuticals, Inc.

|||||||||| New P1 trial: PISH-2: A Phase 1 Trial of Perfusion Induced Systemic Hyperthermia (PISH) Over Multiple Cycles for Terminal Ovarian Cancer (clinicaltrials.gov) - Mar 19, 2014
P1, N=20, Recruiting, Sponsor: ThermalCore Inc

||||||||||  Votrient (pazopanib) / Novartis, BeiGene
Trial completion, Monotherapy, Metastases:  Efficacy and Safety of Pazopanib Monotherapy After First-line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Asian Women (clinicaltrials.gov) -  Mar 19, 2014
P2, N=145, Completed,  Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed

|||||||||| Enrollment open: Genetic Etiology in Premature Ovarian Insufficiency (clinicaltrials.gov) - Mar 17, 2014
P=N/A, N=100, Recruiting, Sponsor: BEGUM AYDOGAN
Active, not recruiting --> Completed Not yet recruiting --> Recruiting

|||||||||| New P2 trial: 2D vs 3D Planning for High-Dose Rate (HDR) Gynecological Brachytherapy (clinicaltrials.gov) - Mar 17, 2014
P2, N=60, Not yet recruiting, Sponsor: AC Camargo Cancer Center

||||||||||  Korlym (mifepristone) / Corcept Therap
Enrollment open, Combination therapy, Metastases:  Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors (clinicaltrials.gov) -  Mar 17, 2014
P1, N=40, Recruiting,  Sponsor: Corcept Therapeutics
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting

||||||||||  remifentanil / Generic mfg.
Enrollment open:  ONSD According to the Position During Laparoscopy (clinicaltrials.gov) -  Mar 17, 2014
P=N/A, N=60, Recruiting,  Sponsor: Chosun University Hospital
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting

|||||||||| Trial termination: Intracutaneous Sterile Water Injections (clinicaltrials.gov) - Mar 16, 2014
P=N/A, N=8, Terminated, Sponsor: Northwestern University
Not yet recruiting --> Recruiting Recruiting --> Terminated; low qualified candidate enrollment

|||||||||| Enrollment change: Intracutaneous Sterile Water Injections (clinicaltrials.gov) - Mar 16, 2014
P=N/A, N=8, Terminated, Sponsor: Northwestern University
Recruiting --> Terminated; low qualified candidate enrollment N=200 --> 8

|||||||||| Enrollment change: Patient Reported Symptoms in Ovarian Cancer (PRECISION) (clinicaltrials.gov) - Mar 16, 2014
P=N/A, N=56, Active, not recruiting, Sponsor: Genentech
N=200 --> 8 N=152 --> 56

||||||||||  ficlatuzumab (AV-299) / AVEO
Clinical:  Protocol to Allow Continued Access of Ficlatuzumab to P05538 Patient (clinicaltrials.gov) -  Mar 16, 2014
P=N/A, N=0, Available,  Sponsor: AVEO Pharmaceuticals, Inc.

|||||||||| Enrollment closed: Patient Reported Symptoms in Ovarian Cancer (PRECISION) (clinicaltrials.gov) - Mar 16, 2014
P=N/A, N=56, Active, not recruiting, Sponsor: Genentech
N=152 --> 56 Recruiting --> Active, not recruiting

|||||||||| Enrollment closed: YKL-40 in Serum Samples From Patients With Newly Diagnosed Stage III-IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Receiving Chemotherapy (clinicaltrials.gov) - Mar 16, 2014
P=N/A, N=2500, Active, not recruiting, Sponsor: Gynecologic Oncology Group
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting

|||||||||| Enrollment closed, IO biomarker, Surgery, Metastases: Glycoprotein and Glycan in Tissue and Blood Samples of Patients With Stage IB-IVA Cervical Cancer Undergoing Surgery to Remove Pelvic and Abdominal Lymph Nodes (clinicaltrials.gov) - Mar 16, 2014
P=N/A, N=286, Active, not recruiting, Sponsor: Gynecologic Oncology Group
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting

||||||||||  otesaconazole (VT-1161) / Mycovia Pharma
Enrollment closed:  A Study to Evaluate the Efficacy and Safety of Oral VT-1161 in Patients With Acute Vaginal Candidiasis (Yeast Infection) (clinicaltrials.gov) -  Mar 13, 2014
P2, N=48, Active, not recruiting,  Sponsor: Viamet Pharmaceuticals, Inc.
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting

|||||||||| Trial completion, Preclinical: TBA on IVF: Impact of Sperm DNA Integrity on In Vitro Cycles (clinicaltrials.gov) - Mar 13, 2014
P=N/A, N=420, Completed, Sponsor: North Shore Long Island Jewish Health System
Recruiting --> Active, not recruiting Active, not recruiting --> Completed

|||||||||| Enrollment open, MRI: Preoperative Staging of Endometriosis With MRI (clinicaltrials.gov) - Mar 13, 2014
P=N/A, N=70, Recruiting, Sponsor: Universitaire Ziekenhuizen Leuven
Active, not recruiting --> Completed Not yet recruiting --> Recruiting

|||||||||| Clinical: Rad_PBS;Radical_PBS: Prophylactic Salpingectomy for the Prevention of the Ovarian Cancer: Comparison Between Surgical Techniques (clinicaltrials.gov) - Mar 11, 2014
P=N/A, N=175, Recruiting, Sponsor: University Magna Graecia

|||||||||| Trial completion, Preclinical: Chronic Endometritis in Patients With Recurrent Miscarriages or Repeated Implantation Failures in In-vitro Fertilization (clinicaltrials.gov) - Mar 11, 2014
P=N/A, N=60, Completed, Sponsor: OVO R & D
Not yet recruiting --> Recruiting Recruiting --> Completed

||||||||||  Menopur (menotropin) / Ferring, Bravelle (urofollitropin) / Ferring
Trial completion, Preclinical:  Effect of a Higher Than Maximum 450IU Gonadotropin Dose in an In-vitro Fertilization Cycle (clinicaltrials.gov) -  Mar 11, 2014
P3, N=366, Completed,  Sponsor: OVO R & D
Recruiting --> Completed Active, not recruiting --> Completed

|||||||||| Biomarker, Trial termination: Tumor Perfusion and Hypoxia Assessed by DCE-MRI and 18F-FMISO PET as Biomarkers of Treatment Response in Cervical Cancer (clinicaltrials.gov) - Mar 11, 2014
P=N/A, N=3, Terminated, Sponsor: Memorial Sloan-Kettering Cancer Center
Active, not recruiting --> Completed Recruiting --> Terminated; Lack of accrual

||||||||||  metformin / Generic mfg., clomifene citrate / Generic mfg.
Trial suspension:  Clomifene Citrate Versus Metformin in First-line Treatment of Infertility in Patients With Polycystic Ovary Syndrome and a Resistance to Insulin (clinicaltrials.gov) -  Mar 11, 2014
P3, N=401, Suspended,  Sponsor: OVO R & D
Recruiting --> Terminated; Lack of accrual Recruiting --> Suspended

|||||||||| Biomarker, Enrollment change: Tumor Perfusion and Hypoxia Assessed by DCE-MRI and 18F-FMISO PET as Biomarkers of Treatment Response in Cervical Cancer (clinicaltrials.gov) - Mar 11, 2014
P=N/A, N=3, Terminated, Sponsor: Memorial Sloan-Kettering Cancer Center
Recruiting --> Suspended N=50 --> 3

||||||||||  metformin / Generic mfg.
New P1 trial:  Targeting Pathways in Polycystic Ovary Syndrome (PCOS) Using Metformin (MET) (clinicaltrials.gov) -  Mar 11, 2014
P1, N=150, Recruiting,  Sponsor: Mayo Clinic

||||||||||  Kombiglyze XR (saxagliptin/metformin XR) / AstraZeneca
Enrollment open, Monotherapy:  BMS-AZPCOS: Saxagliptin + Metformin Compared to Saxagliptin or Metformin Monotherapy in PCOS Women With Impaired Glucose Homeostasis (clinicaltrials.gov) -  Mar 11, 2014
P3, N=36, Recruiting,  Sponsor: BC Women's Hospital & Health Centre
N=50 --> 3 Not yet recruiting --> Recruiting

|||||||||| Enrollment change: PNA FISH, PCR and Gram Staining for Detection of Bacterial Vaginosis - a Comparative Clinical Study in a Danish IVF Setting (clinicaltrials.gov) - Mar 10, 2014
P=N/A, N=150, Active, not recruiting, Sponsor: Regionshospitalet Viborg, Skive
Not yet recruiting --> Recruiting N=100 --> 150

|||||||||| New P2 trial: MecillinamCT: Mecillinam for Treatment of Genital Chlamydia Infection (clinicaltrials.gov) - Mar 9, 2014
P2, N=50, Not yet recruiting, Sponsor: Oslo University Hospital

||||||||||  TheraCIM (nimotuzumab) / Daiichi Sankyo, Oncoscience, Biocon
New P3 trial:  Combination of Nimotuzumab Cisplatin-Vinorelbine in First Line Chemotherapy in Recurring-Persistent Cervical Carcinoma (clinicaltrials.gov) -  Mar 9, 2014
P3, N=168, Enrolling by invitation,  Sponsor: National Institute of Cancerolog

||||||||||  docetaxel / Generic mfg.
New P1 trial:  LDFWART With Docetaxel in Patients With Platinum-Resistant Recurrent Ovarian Carcinoma (clinicaltrials.gov) -  Mar 9, 2014
P1, N=12, Not yet recruiting,  Sponsor: University of Miami Sylvester Comprehensive Cancer Center

||||||||||  Vyleesi (bremelanotide) / Palatin Technologies
Enrollment change:  Bremelanotide in Premenopausal Women With Female Sexual Arousal Disorder and/or Hypoactive Sexual Desire Disorder (clinicaltrials.gov) -  Mar 6, 2014
P2, N=612, Completed,  Sponsor: Palatin Technologies
N=100 --> 150 N=400 --> 612

|||||||||| New P1/2 trial: Edessy ICSI Outcome Embryo Score (EIOS) Efficacy (clinicaltrials.gov) - Mar 6, 2014
P1/2, N=243, Completed, Sponsor: Al-Azhar University

||||||||||  Vyleesi (bremelanotide) / Palatin Technologies
Trial completion:  Bremelanotide in Premenopausal Women With Female Sexual Arousal Disorder and/or Hypoactive Sexual Desire Disorder (clinicaltrials.gov) -  Mar 6, 2014
P2, N=612, Completed,  Sponsor: Palatin Technologies
N=400 --> 612 Active, not recruiting --> Completed

|||||||||| HEOR: Survivorship Care Planning in Improving Quality of Life in Survivors of Ovarian Cancer (clinicaltrials.gov) - Mar 6, 2014
P=N/A, N=20, Recruiting, Sponsor: City of Hope Medical Center

||||||||||  dalantercept (ACE-041) / Merck (MSD)
Enrollment change:  Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer (clinicaltrials.gov) -  Mar 5, 2014
P2, N=28, Active, not recruiting,  Sponsor: Gynecologic Oncology Group
Active, not recruiting --> Completed N=52 --> 28

|||||||||| New P1 trial, Metastases: A Study of DOXIL/CAELYX in Patients With Advanced or Refractory Solid Malignancies Including Patients With Ovarian Cancer (clinicaltrials.gov) - Mar 5, 2014
P1, N=42, Not yet recruiting, Sponsor: Janssen Research & Development, LLC

||||||||||  dalantercept (ACE-041) / Merck (MSD)
Enrollment closed:  Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer (clinicaltrials.gov) -  Mar 5, 2014
P2, N=28, Active, not recruiting,  Sponsor: Gynecologic Oncology Group
N=52 --> 28 Suspended --> Active, not recruiting

||||||||||  sunitinib / Generic mfg.
Trial completion, Monotherapy:  Randomized Multicenter Trial With SU11248 Evaluating Dosage,Tolerability,Toxicity and Effectiveness of a Multitargeted Receptor Tyrosine Kinase Inhibitor (clinicaltrials.gov) -  Mar 5, 2014
P2, N=73, Completed,  Sponsor: AGO Study Group
Suspended --> Active, not recruiting Active, not recruiting --> Completed

|||||||||| Enrollment change: FAMIOP: Genetic Analysis of Familial Cases of Premature Ovarian Failure (clinicaltrials.gov) - Mar 3, 2014
P=N/A, N=110, Completed, Sponsor: Assistance Publique - Hôpitaux de Paris
Active, not recruiting --> Completed N=220 --> 110

|||||||||| Trial completion: FAMIOP: Genetic Analysis of Familial Cases of Premature Ovarian Failure (clinicaltrials.gov) - Mar 3, 2014
P=N/A, N=110, Completed, Sponsor: Assistance Publique - Hôpitaux de Paris
N=220 --> 110 Recruiting --> Completed

||||||||||  Norditropin (somatropin) / Novo Nordisk, Cetrotide (cetrorelix) / EMD Serono
Trial initiation date:  IVF/ICSI Protocols in Poor Responders With Growth Hormone (clinicaltrials.gov) -  Mar 3, 2014
P4, N=287, Recruiting,  Sponsor: Woman's Health University Hospital, Egypt
Recruiting --> Completed Initiation date: Jul 2011 --> Sep 2013

||||||||||  Torisel (temsirolimus) / Pfizer
Enrollment closed, Metastases:  Efficacy,Tolerability,Safety of Temsirolimus in Women With Platinum-refractory Ovarian Carcinoma or Advanced Endometrial Carcinoma (clinicaltrials.gov) -  Mar 3, 2014
P2, N=86, Active, not recruiting,  Sponsor: AGO Study Group
Initiation date: Jul 2011 --> Sep 2013 Recruiting --> Active, not recruiting

|||||||||| Enrollment change: Posterior IVS Versus Sacrospinous Suspension in Vaginal Vault Prolapse Repair (clinicaltrials.gov) - Mar 2, 2014
P4, N=49, Completed, Sponsor: Centre Hospitalier Universitaire de N?mes
Recruiting --> Active, not recruiting N=80 --> 49

|||||||||| Trial completion: Posterior IVS Versus Sacrospinous Suspension in Vaginal Vault Prolapse Repair (clinicaltrials.gov) - Mar 2, 2014
P4, N=49, Completed, Sponsor: Centre Hospitalier Universitaire de N?mes
N=80 --> 49 Recruiting --> Completed

|||||||||| Trial initiation date, HEOR: Palliative Care in Improving Quality of Life and Symptoms in Patients With Stage III-IV Pancreatic or Ovarian Cancer (clinicaltrials.gov) - Feb 27, 2014
P=N/A, N=484, Not yet recruiting, Sponsor: City of Hope Medical Center
Recruiting --> Completed Initiation date: Oct 2013 --> Aug 2014

||||||||||  Victoza (liraglutide) / Novo Nordisk
New P4 trial:  LIPT - Liraglutide in Polycystic Ovary Syndrome (clinicaltrials.gov) -  Feb 26, 2014
P4, N=70, Recruiting,  Sponsor: Jens Faber

||||||||||  Baxdela (delafloxacin) / Menarini, Melinta Therap
Enrollment open:  Comparison of Delafloxacin Versus Ceftriaxone for the Treatment of Uncomplicated Gonorrhea (clinicaltrials.gov) -  Feb 26, 2014
P3, N=757, Recruiting,  Sponsor: Melinta Therapeutics, Inc.
Initiation date: Oct 2013 --> Aug 2014 Not yet recruiting --> Recruiting

||||||||||  OvaRex (oregovomab) / CanariaBio
Trial withdrawal, Metastases:  Oregovomab With or Without Cyclophosphamide in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Responded to Second-Line Chemotherapy (clinicaltrials.gov) -  Feb 25, 2014
P=N/A, N=0, Withdrawn,  Sponsor: Gynecologic Oncology Group
Not yet recruiting --> Recruiting Terminated --> Withdrawn

|||||||||| Biomarker, Trial initiation date, IO biomarker, Metastases: Biomarkers in Tumor Tissue Samples From Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer (clinicaltrials.gov) - Feb 25, 2014
P=N/A, N=169, Not yet recruiting, Sponsor: Gynecologic Oncology Group
Terminated --> Withdrawn Initiation date: Jan 2010 --> Jan 2100

|||||||||| Enrollment change: Patient, Physician, and Nurse Factors Associated With Entry Onto Clinical Trials and Finishing Treatment in Patients With Primary or Recurrent Uterine, Endometrial, or Cervical Cancer (clinicaltrials.gov) - Feb 25, 2014
P=N/A, N=781, Active, not recruiting, Sponsor: Gynecologic Oncology Group
Initiation date: Jan 2010 --> Jan 2100 N=410 --> 781



	Diseases Companies Products Productz Mechanisms of Action Sites